Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

May 23 was a significant day for patients, oncologists and investors in the treatment of head and neck cancer. In preparation for presentations at the American Society of Clinical Oncology, or ASCO, both Bicara Therapeutics Inc. (NASDAQ:I am a private investor based out of Toronto, Canada and I have been investing since 2003. After 8 years in Corporate Finance with a Canadian Telecom company I have decided to dedicate myself full-time to the capital markets. I write on Seeking Alpha to demonstrate my financ ...